NDC 72730-202

TRUSELTIQ

Infigratinib

TRUSELTIQ is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Qed Therapeutics, Inc.. The primary component is Infigratinib.

Product ID72730-202_0529ba94-9541-4ce3-8b59-0afb1e44e0f1
NDC72730-202
Product TypeHuman Prescription Drug
Proprietary NameTRUSELTIQ
Generic NameInfigratinib
Dosage FormCapsule
Route of AdministrationORAL
Marketing Start Date2021-05-28
Marketing CategoryNDA /
Application NumberNDA214622
Labeler NameQED Therapeutics, Inc.
Substance NameINFIGRATINIB
Active Ingredient Strength75 mg/1
NDC Exclude FlagN
Listing Certified Through2023-12-31

Packaging

NDC 72730-202-01

1 BLISTER PACK in 1 CARTON (72730-202-01) > 63 CAPSULE in 1 BLISTER PACK
Marketing Start Date2021-05-28
NDC Exclude FlagN
Sample Package?N

Drug Details

NDC Crossover Matching brand name "TRUSELTIQ" or generic name "Infigratinib"

NDCBrand NameGeneric Name
72730-101TRUSELTIQinfigratinib
72730-111TRUSELTIQinfigratinib
72730-202TRUSELTIQinfigratinib
72730-506TRUSELTIQinfigratinib

Trademark Results [TRUSELTIQ]

Mark Image

Registration | Serial
Company
Trademark
Application Date
TRUSELTIQ
TRUSELTIQ
90975538 not registered Live/Pending
QED Therapeutics, Inc.
2020-10-19
TRUSELTIQ
TRUSELTIQ
90262906 not registered Live/Pending
QED Therapeutics, Inc.
2020-10-19
© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.